Updated Prototype Bench Top Version of the Integrated Optical Biosensor Developed at Los Alamos For Research Purposes Now Com...

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP - News) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced that an updated prototype bench top version of the Integrated Optical Biosensor (“IOBS”) , originally developed at Los Alamos for research purposes, is now complete. Along with the updated instrument an entirely new software interface to operate it has been successfully coded and integrated. The new instrument is currently being validated for performance using well characterized biological assays. This is a significant milestone in the cooperative research agreement that was signed between Los Alamos National Laboratory and Biomagnetics, representing a major step in the development of a new point-of-care diagnostic system.

“We are very excited about the progress being made at the Laboratory, especially the assembly of the bench top version of the integrated optical biosensor,” commented Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. He continued, “Now, we will be able to evaluate the assays on this instrument and eventually, start testing human samples for tuberculosis.”

About Biomagnetics Diagnostics Corp.

Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company and an acquirer of other innovative technologies. The Company is currently developing a waveguide-based advanced integrated optical biosensor through its cooperative research and development agreement with Los Alamos National Security, LLC, which will initially be used for cholera, tuberculosis and malaria diagnosis. More information on Biomagnetics Diagnostics Corp. can be seen at www.biomagneticsbmgp.com.

Biomagnetics Diagnostics (CE) (USOTC:BMGP)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024